title: Facial acneiform rash associated with sorafenib.
abstract: Sorafenib is an oral multikinase inhibitor that is useful in the treatment of various solid cancer. We report a patient who developed an acneiform facial eruption during treatment with this medication.
authors.affiliation: Dermatology Department, Ramon y Cajal Hospital, University of Alcalá de Henares, Madrid, Spain. beatriz_fleta@hotmail.com
authors.forename: Beatriz
authors.initials: B
authors.lastname: Fleta-Asín
authors.forename: Sergio
authors.initials: S
authors.lastname: Vañó-Galván
authors.forename: Alejandro
authors.initials: A
authors.lastname: Ledo-Rodríguez
authors.forename: Maite
authors.initials: M
authors.lastname: Truchuelo-Díez
authors.forename: Pedro
authors.initials: P
authors.lastname: Jaén-Olasolo
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced*; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005148:Facial Dermatoses / Q000139:chemically induced*; D017809:Fatal Outcome; D005260:Female; D018323:Hemangioendothelioma, Epithelioid / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery; D016031:Liver Transplantation; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011183:Postoperative Complications / Q000139:chemically induced; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases